Gilead Sciences has announced that Daniel O'Day, the current CEO of Roche's pharmaceutical unit, will become their chief executive effective from March 1 next year. Daniel will replace current CEO John Milligan, after Gilead revealed that John will step down at the end of 2018.Original Article
You may also like
Pharmaceutical Sales Customer Engagement –...
AstraZeneca’s Polyneuropathy Treatment Recommended...
Designing a Strategic Roadmap for Seamless Product...
AAPS PharmSci 360: LBFs and Tackling Oral Biologic...
CHMP Gives Positive Opinion to Novo Nordisk Hemophilia...
GSK, Cambridge to Partner on R&D for Kidney and...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.